Research programme: anticancer therapeutics - Fujitsu/Kowa/University of Tokyo
Latest Information Update: 13 Aug 2014
At a glance
- Originator Fujitsu; Kowa; University of Tokyo
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Jun 2011 Early research in Cancer in Japan (unspecified route)